-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HCW Biologics (NASDAQ:HCWB) Now Covered by Analysts at Jonestrading
HCW Biologics (NASDAQ:HCWB) Now Covered by Analysts at Jonestrading
Jonestrading initiated coverage on shares of HCW Biologics (NASDAQ:HCWB – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
HCW Biologics Trading Down 3.0 %
Shares of HCW Biologics stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 30.24 and a current ratio of 12.52. HCW Biologics has a 12-month low of $1.76 and a 12-month high of $3.32. The firm's 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.28.
Get HCW Biologics alerts:HCW Biologics (NASDAQ:HCWB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.45 million for the quarter.
Insiders Place Their Bets
In other news, CFO Rebecca Byam bought 50,000 shares of HCW Biologics stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the acquisition, the chief financial officer now owns 205,452 shares in the company, valued at $513,630. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have purchased 104,000 shares of company stock worth $265,230. Corporate insiders own 44.00% of the company's stock.Institutional Investors Weigh In On HCW Biologics
An institutional investor recently raised its position in HCW Biologics stock. HighTower Advisors LLC raised its stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) by 2,056.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,598 shares of the company's stock after acquiring an additional 205,598 shares during the quarter. HighTower Advisors LLC owned approximately 0.60% of HCW Biologics worth $588,000 at the end of the most recent quarter. 1.59% of the stock is owned by institutional investors and hedge funds.
About HCW Biologics
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Jonestrading initiated coverage on shares of HCW Biologics (NASDAQ:HCWB – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
据The Fly报道，琼斯交易公司在周一发布的一份研究报告中首次对卡夫生物(纳斯达克代码：HCWB-GET Rating)的股票进行了报道。该经纪公司对该股发布了买入评级和8.00美元的目标价。
HCW Biologics Trading Down 3.0 %
HCW生物制品降价3.0%
Shares of HCW Biologics stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 30.24 and a current ratio of 12.52. HCW Biologics has a 12-month low of $1.76 and a 12-month high of $3.32. The firm's 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.28.
周一，HCW Biologics的股票开盘报2.25美元。该公司的负债权益比率为0.15，速动比率为30.24，流动比率为12.52。HCW Biologics的12个月低点为1.76美元，12个月高位为3.32美元。该公司的50日简单移动均线切入位为2.33美元，200日简单移动均线切入位为2.28美元。
HCW Biologics (NASDAQ:HCWB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.45 million for the quarter.
新华生物(纳斯达克代码：HCWB-GET Rating)最近一次发布财报是在8月12日(星期五)。该公司公布了该季度每股收益(0.10美元)。该公司本季度的收入为45万美元。
Insiders Place Their Bets
内部人士下注
Institutional Investors Weigh In On HCW Biologics
机构投资者看好HCW生物制品
An institutional investor recently raised its position in HCW Biologics stock. HighTower Advisors LLC raised its stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) by 2,056.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,598 shares of the company's stock after acquiring an additional 205,598 shares during the quarter. HighTower Advisors LLC owned approximately 0.60% of HCW Biologics worth $588,000 at the end of the most recent quarter. 1.59% of the stock is owned by institutional investors and hedge funds.
一家机构投资者最近提高了对HCW Biologics股票的头寸。根据HighTower Advisors LLC最近提交给美国证券交易委员会(SEC)的文件，该公司在第一季度将其在纳斯达克生物公司(HKW Biologics Inc.)的股份增加了2,056.0%。该基金在本季度增持了205,598股后，持有215,598股该公司股票。截至最近一个季度末，HighTower Advisors LLC拥有HCW Biologics约0.60%的股份，价值58.8万美元。1.59%的股票由机构投资者和对冲基金持有。
About HCW Biologics
关于HCW生物制品公司
(Get Rating)
(获取评级)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
HCW生物制药公司是一家临床前阶段的生物制药公司，专注于发现和开发针对慢性、低级别炎症和年龄相关疾病的新型免疫疗法。该公司的主导产品包括HCW9218，这是一种可注射免疫疗法，用于治疗胰腺癌、卵巢癌、乳腺癌、前列腺癌和结直肠癌以及肺纤维化患者；以及HCW9302，用于治疗自身免疫性疾病，如斑秃和代谢性疾病。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免费获取StockNews.com关于HCW生物制品的研究报告(HCWB)
- 油价是股市抛售尚未结束的一个令人信服的原因
- 中盘Neurocrine生物科学是井喷后的第三季度报告吗？
- 六面旗帜是一种你不想被困住的旅程
- 愿景氢，现在的愿景能源，将希望寄托在股票拆分上
- Hanesbrand可能发出零售类股本周表现不佳的信号
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《HCW生物制品日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对HCW Biologics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧